Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.

about

Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.

Item

http://www.wikidata.org/entity/Q48168654

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.

@en

Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.

@nl

type

Item

label

Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.

@en

Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.

@nl

prefLabel

Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.

@en

Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.

@nl

P1476

Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome

@en

P2093

Angela Fischer

http://www.w3.org/2001/XMLSchema#string

Barbara Padberg

http://www.w3.org/2001/XMLSchema#string

Jenny Saub

http://www.w3.org/2001/XMLSchema#string

Sara Bastian

http://www.w3.org/2001/XMLSchema#string

Sergio Cogliatti

http://www.w3.org/2001/XMLSchema#string

Ulrich Mey

http://www.w3.org/2001/XMLSchema#string

Urs Schanz

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical implications of the molecular genetics of chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

How we treat Richter syndrome.

Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.

Risk factors for Richter syndrome in chronic lymphocytic leukemia.

Ibrutinib and rituximab induced rapid response in refractory Richter syndrome

The efficacy of ibrutinib in the treatment of Richter syndrome.

Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

P304

370-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HON.2464

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Karin Hohloch

P577

2017-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28681549

http://www.w3.org/2001/XMLSchema#string